About ECS

Founded: n/a
Employees: n/a
CEO: Nan-Maree Schoerie
WebsiteView website: ecs-botanics.com

ECS Botanics Holdings Ltd engages in the cultivation, manufacture, and sale of medicinal cannabis products in Australia and internationally. It is involved in the agriculture business. ECS Botanics Holdings Ltd is based in Murrabit, Australia.

Recent ECS News & Updates

New Risk • Nov 21

New minor risk - Shareholder dilution

The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AU$7.98m market cap, or US$5.14m). Minor Risks Share price has been volatile over the past 3 months (19% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding).

Recent updates

No updates

ECS Botanics Holdings Ltd Stock Price

ECS Share Price Performance

ECS Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

ECS Botanics Holdings Ltd Key Details

About ECS

Recent ECS News & Updates

New major risk - Share price stability

ECS Botanics Holdings Ltd (ASX:ECS) Might Not Be As Mispriced As It Looks After Plunging 31%

New minor risk - Shareholder dilution

Recent updates

ECS Botanics Holdings Ltd Competitors

Peak Processing

NeuroScientific Biopharmaceuticals

Vitura Health

Ceryvyn Therapeutics